NIH Grant Watch

Abstract

BioTechniquesVol. 44, No. 3 NIH Grant WatchOpen AccessNIH Grant WatchD. McCormick† & B. Perry†D. McCormick††D. McCormick is editorial director ofBioTechniques. B. Perry is president of NIH Sales, Rockville, MD.Search for more papers by this author & B. Perry††D. McCormick is editorial director ofBioTechniques. B. Perry is president of NIH Sales, Rockville, MD.Search for more papers by this authorPublished Online:16 May 2018https://doi.org/10.2144/000112774AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail EpigeneticsThis month, BioTechniques and NIH Sales reviewed the 67,648 grants made by the NIH during 2007 to see how many planned epigenetic studies. Of the abstracts searched, 484 included discussions of epigenesis; these proposals won $195 million in funding. Unsurprisingly, the National Cancer Institute awarded 44% of the funds, followed at a distance by the National Institute of General Medical Sciences (10.1%), the National Institute of Child Health and Development (7.5%), and the National Institute of Environmental Health Sciences (6.1%). Five of the grants, including three of the ten largest, proposed Specialized Programs of Research Excellence (SPOREs). Featured here are recipients of the largest grants.Cancer Center Support Grant $3,387,817.00(5P30CA030199-27, National Cancer Institute, 5/1/2007)Kristiina Vuori (Burnham Institute for Medical Research, La Jolla, CA)Goal: To continue progress in the Center's six program areas: 1) cell adhesion and extracellular matrix; 2) glycobiology; 3) oncodevelopmental biology; 4) cancer genetics and epigenetics; 5) signal transduction research; and 6) apoptosis and cell death. To encourage the use of small molecules as probes for studies of normal and cancer cell biology, and to develop lead compounds that might serve as candidates for further development as anticancer drugs.Barrett's Esophagus: Predictors of Progression $2,428,948.00(2P01CA091955-06, National Cancer Institute, 8/13/2007)Brian J. Reid (Fred Hutchinson Cancer Research Center, Seattle, WA)Goal: To investigate Barrett's esophagus (BE), a unique in vivo model of human epithelial neoplasia and the only established precursor to esophageal adenocarcinoma (EA), a highly lethal malignancy whose incidence has increased more than 600 percent in three decades.University of Texas M.D. Anderson Cancer Center SPORE in Leukemia $2,363,102.00(5P50CA100632-05, National Cancer Institute, 6/19/2007)Jean-Pierre J. Issa (University of Texas M.D. Anderson Cancer Center, Houston, TX)Goal: In collaboration with the University of Texas Southwest Medical Center, to cultivate significant translational research into the biologic, genetic, and clinical aspects of leukemia to improve understanding and therapy. The program includes projects in: epigenetics of drug resistance in acute leukemia; adoptive cellular therapy for myeloid leukemia; concerted blockade of oncoprotein activity; PPAR-gamma nuclear transcription factor, a novel target for leukemia therapy; molecular epidemiology of AML risk and progression; and response of AML patients to FLT3 inhibitors.Johns Hopkins SPORE in Lung Cancer $2,359,850.00(5P50CA058184-13, National Cancer Institute, 6/21/2007)Stephen B. Baylin (Johns Hopkins University, Baltimore, MD)Goal: To provide new means for preventing, detecting, and treating lung cancers of all types. The program includes studies of epigenetic molecular markers with promise in risk assessment, early detection, gauging, and prognosis.University of Texas Southwest Medical Center SPORE in Lung Cancer $2,353,640.00(5P50CA070907-10, National Cancer Institute, 9/17/2007)John D. Minna (University of Texas Southwest Medical Center, Dallas, TX)Goal: In collaboration with the University of Texas M.D. Anderson Cancer Center, to identify and understand the molecular “hallmarks of lung cancer” and translate this information into the clinic. The program includes: identification and exploitation of key lung cancer tumor suppressor genes; identification of inherited and acquired factors that increase risk; identification of abnormalities in apoptosis and invasion during lung cancer pathogenesis; understanding of signaling pathways presenting new targets for chemoprevention and therapy; and development of therapies directed against telomerase.Center for Genomic Experimentation and Computation $2,336,126.00(5P50HG002370-05, National Human Genome Research Institute, 8/16/2007)Roger Brent (Molecular Sciences Institute, Berkeley, CA)Goal: To establish a center that combines functional genomic and computational research to model a prototype signal transduction pathway. The program will focus on gaining the ability to predict the behavior of a well-studied biological regulatory system (the G-protein receptor coupled signal-transduction pathway governing the response of haploid MATa S. cerevisiae to the mating pheromone, a factor) at the level of individual cells.FiguresReferencesRelatedDetails Vol. 44, No. 3 Follow us on social media for the latest updates Metrics Downloaded 136 times History Published online 16 May 2018 Published in print March 2008 Information© 2008 Author(s)PDF download